Gaudium IVF & Women Health IPO Day 3: Check GMP, Subscription Status & Key Highlights

24 February 2026
2 min read
whatsapp
facebook
copyToClipboard

The Initial Public Offering (IPO) for Gaudium IVF & Women Health Ltd is closing today on February 24, 2026. The allotment date for the Gaudium IVF & Women Health IPO is finalised as February 25, 2026 and the tentative listing date is fixed as February 27, 2026. The shares will be listed on both NSE and BSE. Gaudium IVF & Women Health Ltd is known for providing in vitro fertilisation (IVF) treatment and reproductive healthcare services in India.

Gaudium IVF & Women Health IPO - Issue Details

  • Issue Size: Gaudium IVF & Women Health IPO is a bookbuild issue of ₹165.00 crores. It is a combination of fresh issue of 1.14 crore shares aggregating to ₹90.00 crores and offer for sale (OFS) of 0.95 crore shares aggregating to ₹75.00 crores.
  • Price Band: ₹75 to ₹79 per share
  • Minimum lot size: 189
  • Minimum investment for retail individual investors (RIIs): ₹14,175
  • Book-running lead managers: Sarthi Capital Advisors Private Limited
  • Registrar: Bigshare Services Private Limited is the registrar

Gaudium IVF & Women Health IPO Day 3 Subscription Status

[February 24, 2026, 11:18 A.M.]

On Day 3, Gaudium IVF & Women Health IPO saw a subscription of 4.14 times as per NSE data on February 24, 2026, 11:18 am. The public issue was subscribed 5.29 times by the Retail Individual Investors (RIIs), 6.93 times by the Non Institutional Investors (NIIs) and 0.04 times by the Qualified Institutional Buyers (QIBs).

Explore other Upcoming IPOs on BSE and NSE.

Utilisation of IPO Proceeds

The Company will utilise the net proceeds from the fresh issue towards the following purposes:

  • Funding capital expenditure towards establishment of New IVF Centers of the Company.
  • Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company.
  • General Corporate Purposes.

Check out newly Listed IPOs on BSE and NSE.

Gaudium IVF & Women Health Ltd GMP

As per media reports, the Grey Market Premium (GMP) of Gaudium IVF & Women Health Ltd is reported at ₹5 or 6.33% over the upper end of the price band.

Gaudium IVF & Women Health Ltd - Business Overview

Gaudium IVF & Women Health Ltd is a Delhi-based healthcare company founded in March 2015 by Dr. Manika Khanna. It specialises in fertility and women’s health services, offering treatments such as In Vitro Fertilization (IVF), ICSI, IUI, genetic testing (PGT), male infertility care, and high-risk pregnancy support through a hub-and-spoke network of clinics across India.

The company operates over 30 centres,  including 7 hub centres and 28 spoke units providing advanced assisted reproductive technologies and comprehensive women’s health care in major cities. In FY25 (year ended March 31, 2025), the company reported a revenue of about ₹70.96 crore, up from ₹48.15 crore in FY24, and profit after tax (PAT) of around ₹19.13 crore, nearly doubling year-on-year.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here

Do you like this edition?